Enhancement of antioxidant defense mechanism by pitavastatin and rosuvastatin on obesity-induced oxidative stress in Wistar rats

References

• André A, Gonthier MP. 2010. The endocannabinoid system: its roles in energy balance and potential as a target for obesity treatment. Int J Biochem Cell Biol 42:1788–1801.
   PubMedGoogle Scholar
• Aoki T, Yoshinaka Y, Yamazaki H, Suzuki H, Tamaki T, Sato F, Kitahara M, Saito Y. 2002. Triglyceride-lowering effect of pitavastatin [corrected] in a rat model of postprandial lipemia. Eur J Pharmacol 444:107–113.
   PubMedGoogle Scholar
• Bhandari U, Kumar V, Khanna N, Panda BP. 2010. The effect of high fat diet-induced obesity on cardiovascular toxicity in wistar albino rats. Hum Exp Toxicol DOI: 10.1177/0960327110389499 (In press).
   PubMedGoogle Scholar
• Calberg I, Mannerviek B. 1975. Glutathione reductase levels in rat brain. J Biol Chem 250:5475–5480.
   PubMed Web of Science ®Google Scholar
• Caner M, Dogruman H, Taskin E, Kandil A, Demirci C. 2005. Effects of orlistat and its relationship with nitric oxide in the small intestinal mucosa. Chin J Physiol 48:217–222.
   PubMedGoogle Scholar
• Carmiel-Haggai M, Cederbaum AI, Nieto N. 2005. A high-fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats. FASEB J 19:136–138.
   PubMed Web of Science ®Google Scholar
• Claiborne A. 1985. Catalase activity. In: Greenwald RA (ed). CRC Handbook of methods in oxygen radical research. CRC Press, Boca Raton pp 283–284.
   Google Scholar
• Dixon JB. 2010. The effect of obesity on health outcomes. Mol Cell Endocrinol 316:104–108.
   PubMed Web of Science ®Google Scholar
• Ellman GL. 1959. Tissue sulfhydryl groups. Arch Biochem Biophys 82:70–77.
   PubMed Web of Science ®Google Scholar
• Habig WH, Pabst MJ, Jakoby WB. 1974. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem 249:7130–7139.
   PubMed Web of Science ®Google Scholar
• Han LK, Sumiyoshi M, Zhang J, Liu MX, Zhang XF, Zheng YN, Okuda H, Kimura Y. 2003. Anti-obesity action of Salix matsudana leaves (Part 1). Anti-obesity action by polyphenols of Salix matsudana in high fat-diet treated rodent animals. Phytother Res 17:1188–1194.
   PubMedGoogle Scholar
• Ho TF. 2009. Cardiovascular risks associated with obesity in children and adolescents. Ann Acad Med Singap 38:48–49.
   PubMedGoogle Scholar
• Hsu CL, Yen GC. 2007. Effect of gallic acid on high fat diet-induced dyslipidaemia, hepatosteatosis and oxidative stress in rats. Br J Nutr 98:727–735.
   PubMed Web of Science ®Google Scholar
• Husain K, Mejia J, Lalla J, Kazim S. 2005. Dose response of alcohol-induced changes in BP, nitric oxide and antioxidants in rat plasma. Pharmacol Res 51:337–343.
   PubMed Web of Science ®Google Scholar
• Ishihara Y, Ohmori K, Mizukawa M, Hasan AU, Noma T, Kohno M. 2010. Beneficial direct adipotropic actions of pitavastatin in vitro and their manifestations in obese mice. Atherosclerosis 212:131–138.
   PubMed Web of Science ®Google Scholar
• Izawa S, Inoue Y, Kimura A. 1996. Importance of catalase in the adaptive response to hydrogen peroxide: analysis of acatalasaemic Saccharomyces cerevisiae. Biochem J 320:61–67.
   PubMed Web of Science ®Google Scholar
• Juul K, Tybjaerg-Hansen A, Marklund S, Heegaard NH, Steffensen R, Sillesen H, Jensen G, Nordestgaard BG. 2004. Genetically reduced antioxidative protection and increased ischemic heart disease risk: The Copenhagen City Heart Study. Circulation 109:59–65.
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Milionis HJ, Filippatos TD, Nakou ES, Bairaktari ET, Tselepis AD, Elisaf MS. 2007. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. Clin Ther 29:1403–1414.
   PubMed Web of Science ®Google Scholar
• Kumai T, Oonuma S, Matsumoto N, Takeba Y, Taniguchi R, Kamio K, Miyazu O, Koitabashi Y, Sekine S, Tadokoro M, Kobayashi S. 2004. Anti-lipid deposition effect of HMG-CoA reductase inhibitor, pitavastatin, in a rat model of hypertension and hypercholesterolemia. Life Sci 74:2129–2142.
   PubMedGoogle Scholar
• Lee J, Song KS, Kang J, Lee SH, Lee J. 2009. New trends in medicinal chemistry approaches to antiobesity therapy. Curr Top Med Chem 9:564–596.
   PubMedGoogle Scholar
• Liou W, Chang LY, Geuze HJ, Strous GJ, Crapo JD, Slot JW. 1993. Distribution of CuZn superoxide dismutase in rat liver. Free Radic Biol Med 14:201–207.
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275.
   PubMed Web of Science ®Google Scholar
• Ludman A, Venugopal V, Yellon DM, Hausenloy DJ. 2009. Statins and cardioprotection–more than just lipid lowering? Pharmacol Ther 122:30–43.
   PubMed Web of Science ®Google Scholar
• Marklund S, Marklund G. 1974. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 47:469–474.
   PubMedGoogle Scholar
• Saka M, Obata K, Ichihara S, Cheng XW, Kimata H, Noda A, Izawa H, Nagata K, Yokota M. 2006. Attenuation of ventricular hypertrophy and fibrosis in rats by pitavastatin: potential role of the RhoA-extracellular signal-regulated kinase-serum response factor signalling pathway. Clin Exp Pharmacol Physiol 33:1164–1171.
   PubMedGoogle Scholar
• Miersch S, Sliskovic I, Raturi A, Mutus B. 2007. Antioxidant and antiplatelet effects of rosuvastatin in a hamster model of prediabetes. Free Radic Biol Med 42:270–279.
   PubMedGoogle Scholar
• Mohandas J, Marshall JJ, Duggin GG, Horvath JS, Tiller DJ. 1984. Low activities of glutathione-related enzymes as factors in the genesis of urinary bladder cancer. Cancer Res 44:5086–5091.
   PubMed Web of Science ®Google Scholar
• Mohn A, Catino M, Capanna R, Giannini C, Marcovecchio M, Chiarelli F. 2005. Increased oxidative stress in prepubertal severely obese children: effect of a dietary restriction-weight loss program. J Clin Endocrinol Metab 90:2653–2658.
   PubMed Web of Science ®Google Scholar
• Mutlu-Türkoglu U, Oztezcan S, Telci A, Orhan Y, Aykaç-Toker G, Sivas A, Uysal M. 2003. An increase in lipoprotein oxidation and endogenous lipid peroxides in serum of obese women. Clin Exp Med 2:171–174.
   PubMed Web of Science ®Google Scholar
• Myara I, Alamowitch C, Michel O, Heudes D, Bariety J, Guy-Grand B, Chevalier J. 2003. Lipoprotein oxidation and plasma vitamin E in nondiabetic normotensive obese patients. Obes Res 11:112–120.
   PubMedGoogle Scholar
• Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H. 2005. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care 28:2728–2732.
   PubMed Web of Science ®Google Scholar
• Noji Y, Higashikata T, Inazu A, Nohara A, Ueda K, Miyamoto S, Kajinami K, Takegoshi T, Koizumi J, Mabuchi H; Hokuriku NK-104 Study Group. 2002. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis 163:157–164.
   PubMed Web of Science ®Google Scholar
• Ohkawa H, Ohishi N, Yagi K. 1979. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358.
   PubMed Web of Science ®Google Scholar
• Olusi SO. 2002. Obesity is an independent risk factor for plasma lipid peroxidation and depletion of erythrocyte cytoprotectic enzymes in humans. Int J Obes Relat Metab Disord 26:1159–1164.
   PubMed Web of Science ®Google Scholar
• Pagotto U, Vanuzzo D, Vicennati V, Pasquali R. 2008. Pharmacological therapy of obesity. G Ital Cardiol (Rome) 9:83–93.
   PubMedGoogle Scholar
• Park Sungha Kang, Hyun-Jae, Rim Se-Joong Ha, Jong-Won, Oh Byung-Hee Chung, Namsik, and Cho Seung-Yun. 2005. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in korean patients with hypercholesterolemia. Clin Ther 27:1074–1082.
   PubMedGoogle Scholar
• Powers SK, DeRuisseau KC, Quindry J, Hamilton KL. 2004. Dietary antioxidants and exercise. J Sports Sci 22:81–94.
   PubMed Web of Science ®Google Scholar
• Prakash J, Gupta SK, Kochupillai V, Singh N, Gupta YK, Joshi S. 2001. Chemopreventive activity of Withania somnifera in experimentally induced fibrosarcoma tumours in Swiss albino mice. Phytother Res 15:240–244.
   PubMed Web of Science ®Google Scholar
• Reisin E, Ebenezer PJ, Liao J, Lee BS, Larroque M, Hu X, Aguilar EA, Morse SA, Francis J. 2009. Effect of the HMG-CoA reductase inhibitor rosuvastatin on early chronic kidney injury in obese zucker rats fed with an atherogenic diet. Am J Med Sci 338:301–309.
   PubMed Web of Science ®Google Scholar
• Rizvi F, Iftikhar M, George JP. 2003. Beneficial effects of fish liver preparations of sea bass (Lates calcarifer) versus gemfibrozil in high fat diet-induced lipid-intolerant rats. J Med Food 6:123–128.
   PubMedGoogle Scholar
• Saito Yasushi Yamada, Nobuhiro, Teramoto Tamio Itakura, Hiroshige, Hata Yoshiya Nakaya, Noriaki, Mabuchi Hiroshi Tushima, Motoo, Sasaki Jun Ogawa, Nobuya, Goto Yuichiro. 2002. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 162:373–379.
   PubMedGoogle Scholar
• Silver AE, Beske SD, Christou DD, Donato AJ, Moreau KL, Eskurza I, Gates PE, Seals DR. 2007. Overweight and obese humans demonstrate increased vascular endothelial NAD(P)H oxidase-p47(phox) expression and evidence of endothelial oxidative stress. Circulation 115:627–637.
   PubMed Web of Science ®Google Scholar
• Sowers JR. 1998. Obesity and cardiovascular disease. Clin Chem 44:1821–1825.
   PubMed Web of Science ®Google Scholar
• Susic D, Varagic J, Ahn J, Slama M, Frohlich ED. 2003. Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol 42:1091–1097.
   PubMed Web of Science ®Google Scholar
• Vincent HK, Powers SK, Dirks AJ, Scarpace PJ. 2001. Mechanism for obesity-induced increase in myocardial lipid peroxidation. Int J Obes Relat Metab Disord 25:378–388.
   PubMed Web of Science ®Google Scholar
• Vincent HK, Innes KE, Vincent KR. 2007. Oxidative stress and potential interventions to reduce oxidative stress in overweight and obesity. Diabetes Obes Metab 9:813–839.
   PubMed Web of Science ®Google Scholar
• Watson Angela M., Poloyac Samuel M., Howard Georgette,,and Blouin Robert A. 1999. Effect of leptin on cytochrome P-450, conjugation, and antioxidant enzymes in the Ob/Ob mouse. Drug Metab Dispos 27:695–700.
   PubMedGoogle Scholar
• Weidig P, McMaster D, Bayraktutan U. 2004. High glucose mediates pro-oxidant and antioxidant enzyme activities in coronary endothelial cells. Diabetes Obes Metab 6:432–441.
   PubMed Web of Science ®Google Scholar
• Yesilbursa D, Serdar Z, Serdar A, Sarac M, Coskun S, Jale C. 2005. Lipid peroxides in obese patients and effects of weight loss with orlistat on lipid peroxides levels. Int J Obes (Lond) 29:142–145.
   PubMed Web of Science ®Google Scholar
• Yoshioka Keiji Murakami, Yumi, Ego Kyoko Nakajima, Yasuhiro. 2010. Effect of pitavastatin on serum high-molecular weight (HMW) adiponectin to total adiponectin ratio in type 2 diabetic patients. Diabetes & Metabolic Syndrome. Clin Res Rev 4:95–96.
   Google Scholar
• Zambarakji Hadi J., Nakazawa Toru Connolly, Edward, Lane Anne Marie Mallemadugula, Sreedevi, Kaplan Michael Michaud, Norman, Hafezi-Moghadam Ali, Gragoudas Evangelos S., Miller Joan W. 2006. Dose-dependent effect of pitavastatin on VEGF and angiogenesis in a mouse model of choroidal neovascularization. Invest Ophthalmol Vis Sci 47:2623–2631.
   Google Scholar